Thursday, May 9 2024 | Time 01:37 Hrs(IST)
image
Business EconomyPosted at: May 9 2019 1:07PM


Glenmark Pharma announces results from phase 3 study of Ryaltris

Mumbai, May 9(UNI) Pharma Major, Glenmark Pharmaceuticals, on Thursday announced positive results from a Phase 3 study of Ryaltris, an investigational fixed-dose combination nasal spray for the treatment of seasonal allergic rhinitis (SAR).
The study in patients aged 6 to under 12 years met its primary endpoint in achieving clinically meaningful and statistically significant change from baseline in average morning and evening Reflective Total Nasal Symptom Score (rTNSS) compared to placebo.1 Ryaltris (olopatadine hydrochloride [665 mcg] and mometasone furoate
[25 mcg]), also known as GSP 301 Nasal Spray, has been conditionally accepted by the FDA as the brand name, a release said
''It has become increasingly important to conduct studies specifically designed for pediatric patients, so that we may gain insights into potential differences in safety, efficacy and dosing compared to studies in adult and adolescent populations,'' said Mahboob Rahman, Chief Medical Officer at Glenmark Pharmaceuticals.
''We are pleased to report that the safety and effectiveness observed in this pediatric population is consistent with our overall Phase 3 development program in SAR patients 12 years of age and older. These robust data contribute to the extensive clinical background supporting the effectiveness and tolerability of
Ryaltris''.
The primary objective of the Phase 3 study was to compare the effectiveness of Ryaltris (administered as one spray in each nostril, twice daily) versus a placebo nasal spray over 14 days in pediatric subjects (aged 6 to < 12 year) with SAR. The study randomized 446 patients and 431 patients completed the study (96.6 pc).
In the study, patients treated with Ryaltris compared to placebo showed a statistically significant improvement for the primary endpoint of average morning and evening rTNSS (p=0.001).
Rates of treatment-emergent adverse events (TEAEs) were similar between Ryaltris versus placebo (10.4 pc vs. 12.0 pc, respectively).
The most common TEAEs included distortion of taste sensation (Ryaltris 1.3 pc, placebo 0.0 pc), headache (Ryaltris 1.3%, placebo 0.5 pc) and nose bleed (Ryaltris 0.9 pc placebo 2.3pc).
Glenmark Pharmaceuticals has studied Ryaltris in seven clinical trials involving more than 4,000 adult and adolescent patients (12 years of age and older). Results from those clinical trials of Ryaltris have been previously presented at key medical meetings and full results from the study of Ryaltris in pediatric patients aged 6 to under 12 years of age will be published and presented at future meetings.
If approved by the FDA, Ryaltris will be commercialized by Glenmark Therapeutics Inc. USA, a wholly-owned subsidiary of Glenmark Holding, SA, that is dedicated to launching a portfolio of branded products in the therapeutic areas of respiratory and dermatology in the US.
UNI JS SB 1307
Please log in to get detailed story.
Tags: #Glenmark Pharma announces results from phase 3 study of Ryaltris
More News

Zoomcar to add 20,000 cars in its platform by end of fiscal 2025

08 May 2024 | 8:12 PM

New Delhi, May 8 (UNI) Zoomcar, self-drive car sharing company, on Wednesday announced plans to expand its footprint by adding over 20,000 cars by fiscal year 2025 to its platform for “self-drive” car sharing and provide opportunities to card owners to boost their income by way of sharing their vehicles.

see more..

TVS SCS wins new business deal for Eicher’s bus facility in Baggad

08 May 2024 | 7:54 PM

Chennai, May 8 (UNI) TVS Supply Chain Solutions Limited, a global supply chain solutions provider and one of the largest and fastest-growing integrated supply chain solutions providers in India, has won a new business contract from VE Commercial Vehicles (VECV) for managing their in-plant warehousing and logistics function at their Eicher bus factory located in Baggad, Madhya Pradesh.

see more..

TVS records highest ever revenue, profit in FY 2023-24

08 May 2024 | 7:52 PM

Chennai, May 8 (UNI) Two and three-wheeler major TVS Motor Company’s revenue from operations in the quarter ended March 2024 grew by 24% at Rs. 8,169 Crores against Rs. 6,605 Crores in the quarter ended March 2023.

see more..

AIC T-Hub selects startups to drive innovation in mobility sector

08 May 2024 | 7:17 PM

Hyderabad, May 8 (UNI) T-Hub, India's leading startup incubator, in collaboration with the Atal Incubation Centre (AIC), announced on Wednesday the launch of the mobility cohort of the AIC T-Hub Programme. This initiative is poised to revolutionise the automotive industry's future, with visionary startups selected to participate, Hyderabad-based T-Hub said in a release here.

see more..

AIC T-Hub selects startups to drive Innovation in the Mobility Sector

08 May 2024 | 7:14 PM

Hyderabad, May 8 (UNI) T-Hub, India's leading startup incubator, in collaboration with Atal Incubation Centre (AIC), on Wednesday announced the launch of the mobility cohort of the AIC T-Hub Program.

see more..
image